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Abstract 
Background: We compared women with incident cervical cancer under the age of 30 with older women with 
regard to stage, morphology, screening history and cervical cancer mortality in a population-based cohort study.
Methods: We included data from the Cancer Registry of Norway. Incidence rates (per 100,000 women-years) were 
calculated and joinpoint regression was used to analyse trends. The Nelson-Aalen cumulative hazard function for risk 
of cervical cancer death during a 15-year follow-up was displayed. The hazard ratios (HRs) of cervical cancer mortality 
with 95% confidence intervals (CIs) were derived from Cox regression models.
Results: The incidence of cervical cancer in women under the age of 30 has almost tripled since the 1950s, with 
the steepest increase during 1955–80 (with an annual percentage change (APC) of 7.1% (95%CI 4.4–9.8)) and also 
an increase after 2004 (3.8% (95%CI -1.3–9.2)). Out of 21,160 women with cervical cancer (1953–2013), 5.3% were 
younger than 30 years. A lower proportion of younger women were diagnosed at more advanced stages and a 
slightly higher proportion were diagnosed with adenocarcinoma and adenosquamous carcinoma comparing women 
above 30 years. The cumulative risk of cervical cancer death was lower for patients under the age of 30. However, the 
difference between the age groups decreased over time. The overall adjusted HR of cervical cancer mortality was 0.69 
(95% CI 0.58–0.82) in women diagnosed under the age of 30 compared to older women.
Conclusion: There has been an increase in cervical cancer incidence in women under the age of 30. Cervical cancer 
in younger women was not more advanced at diagnosis compared to older women, and the cervical cancer mortality 
was lower.
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Background
Cervical cancer is the fourth most common cancer in 
women globally and affects women of all ages  [1]. It is 
the second most common form of cancer in women 
15–44 years  [2]. A nationwide cervical cancer screening 
programme was introduced in Norway in 1995  [3]. How-
ever, prior to organized screening, there was extensive 
opportunistic screening  [4, 5]. The primary aim of the 
screening programme is to reduce the incidence and 
mortality of the disease by identifying and treating its 
precursor lesions before they develop into cancer  [6]. 
The programme recommends screening every three 
years for women between 25 and 69  years of age. The 
screening programme is based on reminders and relies 
on centralised registration and monitoring of all cervi-
cal cytology, human papillomavirus (HPV) tests, cervical 
histology and treatment of cervical intraepithelial neopla-
sia (CIN) lesions and cancer  [7]. In 2015, the randomised 
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implementation of HPV primary screening in women 
aged 34–69 commenced in four counties in Norway, 
replacing cytology  [8]. Since 2019, HPV primary screen-
ing is gradually being introduced in the remaining Nor-
wegian counties.
In Norway, a reduction of 68% in total cervical cancer 
incidence due to screening has been estimated  [9]. How-
ever, there has been an increase in cervical cancer inci-
dence in women under 30 years over the past 20–25 years 
in Norway and other European countries, such as the 
UK  [7, 10]. The reasons for the increase are unclear but 
may include changes in sexual behavior and the burden 
of associated sexually transmitted infections, including 
HPV  [10, 11].
In a study from the UK, cervical cancer in young 
women (under 25  years) tended to be more aggressive 
and advanced at the time of diagnosis (stage 1B+ or 
worse) than if diagnosed in older women (25–29  years) 
[10]. Furthermore, a higher proportion of younger 
women were diagnosed with adenosquamous carcinoma 
and other rarer histological types  [10]. Also, the partici-
pation rates in cervical cancer screening programmes 
have slowly decreased in young women in many devel-
oped countries in recent years for no clear reason  [12].
In this study, we aimed to compare stage, histology, 
screening history and subsequent cervical cancer mor-
tality in women diagnosed with cervical cancer under 
30  years of age (overall and stratified into < 25 and 
25–29  years) with those diagnosed with cervical cancer 
at an older age in Norway.
Methods
Data sources
The Cancer Registry of Norway (CRN) was established 
in 1953 and contains mandatory information on all new 
cancer cases and precancerous lesions. Information from 
clinical notifications, pathological notifications and death 
certificates are the main reporting sources and provide 
information about site, histological type and stage of 
disease at the time of diagnosis. The coding and classifi-
cation system at the CRN is in accordance with interna-
tional standards  [13]. The CRN has also recorded causes 
of death for cancer patients (from the Cause of Death 
Registry  [14], run by the Norwegian Institute of Public 
Health), available from 1960.
The Norwegian Cervical Cancer Screening Programme 
(NCCSP) is an integrated part of the national health 
care system. The CRN runs the program and receives 
mandatory reports from private and public pathology 
and microbiology laboratories. The programme keeps 
complete records of the results of all pap smears, histol-
ogy specimens and HPV tests. Individual screening data 
are recorded and organized into four sub-registries: The 
Cytology Register, the Histology Register, the HPV Test 
Register and the CIN Register, the last containing follow-
up and treatment data. The SNOMED coding system, 
with some local adaptations, is used for classification 
(cytology and histology).
All residents in Norway are assigned a unique identi-
fication number used in all administrative and medical 
registries/databases. This identification number enables 
accurate record linkage.
Study population
This cohort study included all women diagnosed with 
cervical cancer (International Classification of Dis-
eases (ICD)-10; C53) in Norway during 1953–2013 
(n = 21,160). No cases with ICD-10 code 55 were 
included. For 34 women who had two cervical cancer 
diagnoses, only the first recorded diagnosis was included.
Statistical analysis
Period of diagnosis (1953–68, 1969–83, 1984–98, and 
1999–13), stage distribution (International Federation 
of Gynecology and Obstetrics: FIGO (1986); stages 1–4), 
morphology (squamous cell carcinoma, adenocarci-
noma, adenosquamous carcinoma, other malignancies 
and unspecified morphology)  [9] and screening history; 
smears taken from 3.5 years and up to six months prior 
to diagnosis (no smear, only normal smears, abnormal 
smears and only unsatisfactory smears), by age groups 
(< 25, 25–29 and ≥ 30 years) were descriptively displayed 
and analysed using contingency tables. Information on 
screening history was available for cancers diagnosed 
from 1 July, 1995 onwards  [15]. Chi-square tests were 
used to evaluate differences in distributions between age 
groups. A p-value below 0.05 was considered statistically 
significant.
Crude incidence rates (per 100,000 women-years) of 
cervical cancer by age group (< 30 and ≥ 30  years) and 
age-standardised rates (World standard population), 
1955–2014, were calculated separately using support-
ing data from the CRN (Fig. 1), taking immigration and 
emigration into account. The temporal trends in age-
standardised rates were estimated using Joinpoint Trend 
Analysis Software from the National Cancer Institute 
(Version 4.8.0.1). We analysed time trends in incidence 
rates in women < 30 and ≥ 30  years. For the joinpoint 
analysis we used age-specific numbers of cervical cancer 
provided by the CRN, population numbers from Statis-
tics Norway, in 12 five-year periods (1955–59, …, 2010–
14) and weights for age-standardisation to the World 
standard population from the WHO  [16]. The whole 
period 1955–2014 was segmented by the points with 
trend change, and the annual percentage change (APC) 
in rates between the trend-change points was estimated. 
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Thereafter, the average annual percent change (AAPC) 
for the whole study period was calculated as a weighted 
average of the estimated APC in each segment by using 
the segment lengths as weights  [17].
The Nelson-Aalen cumulative hazard function for 
risk of death from cervical cancer, with 95% confi-
dence intervals (CIs), during a 15-year follow-up by age 
(< 30 and ≥ 30  years) and period of diagnosis (1960–73, 
1974–86, 1987–99 and 2000–13), was calculated  [18, 
19]. The start of follow-up was from date of diagnosis 
and the individuals were followed up until emigration, 
death, 15  years after diagnosis or end of follow-up on 
31 December, 2016, whichever occurred first. Follow-up 
ended 15  years after diagnosis due to the relatively low 
number of deaths.
Hazard ratios (HRs) of cervical cancer mortality with 
95% CIs, with and without adjustment for stage (FIGO 
stages 1–4), morphology (squamous cell carcinoma, 
adenocarcinoma, adenosquamous carcinoma, other 
malignancies and unspecified morphology) and time 
of diagnosis (continuous), were derived from Cox pro-
portional hazard regression models. We also presented 
estimates for specific periods of diagnosis (1960–73, 
1974–86, 1987–99 and 2000–13).
The data were analysed using IBM SPSS Statistics 22 
(IBM Corporation, Armonk, NY, USA) and Stata/IC 14.0 
(StataCorp LP, College Station, TX, USA).
Results
Since the 1950s, the incidence of cervical cancer in 
women aged < 30 increased from 0.9 per 100,000 women-
years in 1955–59 to 2.6 in 2010–14) (Fig.  1). However, 
the increase has not been steady. The joinpoint regres-
sion analysis identified two joinpoints, in 1980 and 
2005. After a peak in the 1970s (APC in incidence was 
7.1% (95% CI 4.4–9.8) during 1955–80), the incidence 
slightly decreased in 1980–2005 (APC in incidence was 
-2% (95%CI -3.5–0.0)) and then increased slightly again 
after 2004 (APC in incidence was 3.8% (95% CI -1.3–9.2) 
during 2005–14). For the whole period 1955–2014, the 
AAPC in incidence was 2.3% (9% CI 1.2–3.4). In contrast, 
in women aged ≥ 30, the incidence was 31.7 in 1955–59 
and declined after a peak in the early 1970s to 18.8 in 
2010–14.
The main analysis included a total of 21,160 women 
diagnosed with cervical cancer in Norway during 1953–
2013. Table  1 summarises the characteristics of these 
women by age at diagnosis. Most women were above 
30  years (94.7%). Cervical cancer was rare in women 
under 25 years of age, with only 207 cases (0.98%) in this 
age group. In women under 30  years, 87.0% in the age 
group < 25 years and 82.4% in the age group 25–29 years 
were diagnosed at stage 1, whereas in women above 
30 years, 51.8% were diagnosed at stage 1.
In all cases, the proportion of women diagnosed with 
stage 1 cancer increased from 42.4% in 1953–68 to 
58.8% in 1999–2013. The corresponding proportions 
in women < 30 years were 59.7% and 81.4%, respectively 
(Table 2). The majority of women in all age groups were 
diagnosed with squamous cell carcinoma, but a slightly 
higher proportion of women under 30  years were diag-
nosed with adenocarcinoma and adenosquamous carci-
noma compared to women above 30 years (Table 1). For 
women with adenocarcinoma and adenosquamous cell 
carcinoma, a higher proportion were diagnosed at stage 1 
(Table 3) than for women with squamous cell carcinoma. 
For women under 30  years with adenocarcinoma and 
adenosquamous carcinoma, 83.1 and 77.5%, respectively, 
were diagnosed at stage 1.
We only had data on screening history available for 
those women diagnosed from 1 July, 1995 when the 
national screening programme started. Overall, 60.3% 
of these women did not have smears taken during the 
3.5-year period preceding diagnosis; the corresponding 
proportion was 62.0% in women above 30  years, 38.7% 
in women < 25  years and 36.8% in women 25–29  years 
(Table  1). Also, a higher proportion of women in the 
younger age group had only normal smears before diag-
nosis (age < 25; 40.3% and age 25–29; 36.8%), when 
compared to women above 30  years of age (25.0%). In 
women under 30  years of age, 21.0% of women under 
25 years and 23.5% of women 25–29 years had abnormal 
smears 3.5 years before diagnosis; 11.6% in women above 
30  years. Additional file  1:  Table  1 (Table  S1) displays 
similar figures for women in the target age range of the 
screening programme (25–69 years).
Figure 2 shows the cumulative risk of death from cer-
vical cancer during a 15-year follow-up by age (< 30 






















Fig. 1 Crude incidence rates (per 100,000 women-years) by age 
(< 30 and ≥ 30 years) and age-standardised rates (World standard 
population) of cervical cancer, Norway, 1955–2014
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1974–86, 1987–99 and 2000–13). The cumulative risk of 
death from cervical cancer decreased with calendar time 
for women both under and above 30 years of age. How-
ever, the difference between the age groups decreased. 
The cumulative risk of death from cervical cancer after 
15  years of follow-up was higher for women ≥ 30  years 
than for women < 30  years in all four time periods that 
were studied.
In the Cox regression analysis of cervical cancer mor-
tality (1960–2013), the women were followed for an 
Table 1 Characteristics of women diagnosed with cervical cancer in Norway by age, 1953–2013
a p-values for difference: Chi-square tests between age groups
b Smears taken from 3.5 years and up to six months prior to diagnosis, available from 1 July, 1995
c Cytology diagnosis of atypical squamous cells of undetermined significance or more severe
All ages Age < 25 Age 25–29 Age ≥ 30 p-differencea
n % n % n % n %
Period of diagnosis
1953–68 5,495 26.0 13 6.3 106 11.6 5,376 26.8
1969–83 6,168 29.1 85 41.1 263 28.7 5,820 29.0
1984–98 5,089 24.1 59 28.5 290 31.7 4,740 23.7
1999–13 4,408 20.8 50 24.2 256 28.0 4,102 20.5  < 0.001
Stage (FIGO)
1 11,322 53.5 180 87.0 754 82.4 10,388 51.8
2 5,236 24.7 19 9.2 103 11.3 5,114 25.5
3 2,775 13.1 3 1.4 33 3.6 2,739 13.7
4 1,487 7.0 3 1.4 9 1.0 1,475 7.4
Unknown 340 1.6 2 1.0 16 1.7 322 1.6  < 0.001
Morphology
Squamous cell carcinoma 17,565 83.0 164 79.2 745 81.4 16,656 83.1
Adenocarcinoma 2,284 10.8 26 12.6 104 11.4 2,154 10.7
Adenosquamous carcinoma 374 1.8 6 2.9 34 3.7 334 1.7
Other malignancies 880 4.2 10 4.8 28 3.1 842 4.2
Unspecified morphology 57 0.3 1 0.5 4 0.4 52 0.3  < 0.001
Total 21,160 100.0 207 100.0 915 100.0 20,038 100.0
Screening historyb
No smear 3,371 60.3 24 38.7 119 36.8 3,228 62.0
Only normal smears 1,445 25.9 25 40.3 119 36.8 1,301 25.0
Abnormal  smearsc 694 12.4 13 21.0 76 23.5 605 11.6
Only unsatisfactory smears 78 1.4 0 0 9 2.8 69 1.3  < 0.001
Total 5,588 100.0 62 100.0 323 100.0 5,203 100.0
Table 2 FIGO stage by age and period of diagnosis (%) for women diagnosed with cervical cancer in Norway, 1953–2013
Age at diagnosis Period of diagnosis
Stage 1953–68 1969–83 1984–98 1999–2013 Total
 < 30 years (n = 119) (n = 348) (n = 349) (n = 306) (n = 1,122)
1 59.7 88.5 87.7 81.4 83.2
2+ 38.7 10.1 10.9 16.7 15.2
Unknown 1.7 1.4 1.4 2.0 1.6
 ≥ 30 years (n = 5,376) (n = 5,820) (n = 4,740) (n = 4,102) (n = 20,038)
1 42.0 53.4 56.5 57.1 51.8
2+ 56.2 45.3 42.6 40.2 46.6
Unknown 1.8 1.3 0.8 2.7 1.6
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average of 8.7  years (range; 0–15  years), constituting 
163,500 women-years. During follow-up, 5,980 cervi-
cal cancer deaths were identified. The overall unadjusted 
and adjusted HRs of cervical cancer mortality were 0.38 
(95%CI 0.32–0.45) and 0.69 (95% CI 0.58–0.82), respec-
tively, in women diagnosed under the age of 30 compared 
to older women (Additional file  2: Table  S2). The HRs 
(adjusted for stage and morphology) for the diagno-
sis periods 1960–73, 1974–86, 1987–99 and 2000–13 
were 0.78 (95%CI 0.55–1.13), 0.74 (95%CI 0.56–0.97), 
0.56 (95%CI 0.40–0.80), and 0.66 (95%CI 0.43–1.01), 
respectively.
Table 3 FIGO stage by age at diagnosis and morphology (%) for women diagnosed with cervical cancer in Norway, 1953–2013





Other malignancies Unspecified 
morphology
Total
 < 30 years (n = 909) (n = 130) (n = 40) (n = 38) (n = 5) (n = 1,122)
1 84.5 83.1 77.5 63.2 60.0 83.2
2+ 14.6 13.1 22.5 28.9 0.0 15.2
Unknown 0.9 3.8 0.0 7.9 40.0 1.6
 ≥ 30 years (n = 16,656) (n = 2,154) (n = 334) (n = 842) (n = 52) (n = 20,038)
1 51.2 61.5 56.6 39.9 21.2 51.8
2+ 47.5 36,4 42.8 53.0 69.2 46.6
Unknown 1.3 2.1 0.6 7.1 9.6 1.6
Fig. 2 Cumulative risk of death* from cervical  cancer#, with 95% confidence intervals, during 15 years of follow-up by age (< 30 and ≥ 30 years) and 
period of diagnosis (1960–73, 1974–86, 1987–99 and 2000–13). * Nelson-Aalen cumulative hazard function, unadjusted estimates  [18, 19]. # 5,980 
cervical cancer deaths
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Discussion
The incidence of cervical cancer in women under 
30 years of age has almost tripled since the 1950s, while 
decreasing overall. Nevertheless, only a small propor-
tion of women diagnosed with cervical cancer were 
under 30 years of age. In our study, cancers in younger 
women were of earlier stage, and only a slightly higher 
proportion of women had adenocarcinoma and aden-
osquamous carcinoma compared to women above 
30  years of age. Mortality from cervical cancer was 
lower for women under the age of 30 even after adjust-
ing for stage. The screening history of women with 
cervical cancer under the age of 30 differed from 
those older at the time of diagnosis. A larger propor-
tion of the younger women with cancer had preceding 
screening tests, both normal and abnormal. This may 
reflect poorer effectiveness of screening in younger age 
groups, as has been suggested by a number of past pub-
lications  [20–22].
One of the strengths of this study was its population-
based design, including all women with cervical cancer 
in Norway since the 1950s. Our data set did not include 
information on hysterectomy. Due to the missing infor-
mation on hysterectomy, incidence rates particularly 
among women above 30 years, are likely underestimated 
as the rates of hysterectomy increase with age. However, 
the rates of hysterectomy are relatively low in Norway 
compared to other Western countries [23–25].
Another limitation of the study was the relatively low 
number of cervical cancer cases in women in the young-
est age groups. Also, when examining the screening 
history in women above the age of 25, we were unable 
to separate the cytology tests following an invitation to 
screening from those taken in response to symptoms. In 
the NCCSP, women are invited to be screened from the 
age of 25. However, the results of all smears (in all age 
groups) are recorded. Since women under 25  years of 
age were not part of the national screening programme 
for the entire period, self-selection for screening may be 
more pronounced in this age group and could be influ-
enced by factors such as the use of contraception and 
associated visits to health care providers, the healthy 
screenee effect, as well as symptoms.
The cervical cancer screening programme from 1995 
with written invitations for pap smears every third year 
increased coverage of the target population  [26]. For 
women 25–39 years of age there was a decrease in cover-
age until 2012. However, from 2012 onwards, increased 
coverage has been noted, particularly in women aged 
25–34 years. This could be attributable to media coverage 
and projects aimed at increasing screening attendance, 
such as the "Sjekk deg-kampanjen" ran by the Norwegian 
Cancer Society  [7].
A study from Canada published in 2001  [27] con-
cluded that the incidence of invasive cervical adenocarci-
noma and adenosquamous carcinoma had been steadily 
increasing in women 20–49 years of age. Another study 
from the UK published in 2011 showed that the incidence 
of cervical cancer in women 20–29 years of age increased 
significantly after 1992  [11]. On the contrary, a US study 
(2017) concluded that the incidence of invasive cervical 
cancer in younger women aged 21–25 was very low and 
declined significantly between 2000 and 2013  [28]. How-
ever, among 24–25-year-olds the incidence remained 
constant. Our study showed that the cervical cancer rate 
in women under the age of 30 has almost tripled since 
the  1950s.  However, the incidence of cervical cancer in 
women both above and under 30  years peaked in the 
1970s when opportunistic screening became widespread, 
with a further decline after the screening programme 
started. Overall, the proportion of women diagnosed 
at stage 1 increased over time, and the proportion also 
increased in women diagnosed under 30 years of age.
A study from the UK published in 2013 concluded that 
cervical cancer in young women was rare and that only 
a small group of women 20–29  years of age had been 
diagnosed with cervical cancer before the age of 25  [10]. 
Similarly, in our data, only around 1% of the cancers 
were diagnosed before the age of 25. Like the UK study, 
our study also showed that a clear majority of women 
diagnosed at < 30  years were diagnosed at stage 1. The 
same study from the UK concluded that cervical cancer 
in young women (aged 20–24 years) tended to be more 
advanced and was often of a rarer histological type than 
cancers in older women  [10]. In our study, a slightly 
higher proportion of women in the younger age groups 
(under 30  years) were diagnosed with either adenocar-
cinoma or adenosquamous carcinoma, but the cancers 
in general did not tend to be more advanced. Also, for 
younger women with adenocarcinoma or adenosqua-
mous carcinoma the majority were diagnosed at stage 1.
A Canadian study from 2012 showed the link between 
invasive cervical cancer and mortality in young women 
15–29  years of age. The study concluded that both the 
disease and mortality among these women were rare, 
and had declined during the study period (1970–2007) 
[29]. Also, an earlier Hungarian study showed no differ-
ences in survival among the different age groups, and 
concluded that cervical cancer in young women was not 
more aggressive than in other age groups  [30]. A further 
study from England (2012) found that 91% of younger 
women with cervical cancer were diagnosed at stage 
1A or 1B and had an excellent prognosis  [31]. All these 
studies support the results of our study, showing a lower 
cervical cancer mortality for younger women, when com-
pared to older women. The absolute difference in the 
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cumulative risk of death from cervical cancer between 
the two age groups in the current study decreased with 
calendar time, particularly in the periods since 1987. 
This is probably due to the much stronger impact of the 
organised screening programme on both incidence and 
mortality in the age groups above 30 years.
There are still varying opinions regarding the appropri-
ate age to start cervical screening. European guidelines 
recommend that screening should start from 25–30 years 
[32]. Australia’s programme starts from age 18  [33], 
whereas the screening programmes in Finland and The 
Netherlands start at the age of 30  [34]. Studies have con-
cluded that screening below the age of 25 leads to signifi-
cant over-treatment with an uncertain impact on cervical 
cancer incidence and mortality  [33, 35]. A study from 
the UK also concluded that the increase in cervical can-
cer in young women cannot be attributed to the lack of 
screening of women aged 20–24 years  [31].
In 2009, HPV vaccination was introduced in the Nor-
wegian national vaccination programme for girls in pri-
mary school and also included boys from autumn 2018 
[36]. It is too early to quantify the long-term effects of 
the vaccination in Norway, but it is expected that the 
incidence of cervical cancer in vaccinated women will 
decrease rapidly. Both vaccines used in Norway have 
demonstrated good efficacy against the high-risk HPV 
types 16 and 18, responsible for an estimated 73% of cer-
vical cancer cases in Europe  [37, 38]. HPV vaccination 
will likely affect the incidence of cervical cancer overall 
due to herd immunity, particularly given the high vacci-
nation coverage in Norway.
Conclusions
Even though only a relatively small number of cervical 
cancers occurs in women under 30 years of age, rates in 
this age group have almost tripled in Norway since the 
1950s. Cancer in young women does not tend to be more 
advanced at diagnosis, compared to older women. Also, 
the mortality from cervical cancer appears to be lower for 
women in the younger age groups. While the effective-
ness of screening may be age-dependent, hopes are raised 
for an eventual decrease in cervical cancer burden across 
all age groups due to HPV immunisation through the 
Norwegian national vaccination programme from 2009 
for all girls born after 1996.
Abbreviations
CI: Confidence interval; CIN: Cervical intraepithelial neoplasia; CRN: Cancer 
Registry of Norway; FIGO: International Federation of Gynecology and Obstet-
rics; HPV: Human papillomavirus; HR: Hazard ratio; ICD: International Classifica-
tion of Diseases; NCCSP: Norwegian Cervical Cancer Screening Programme.
Supplementary information
The online version contains supplementary material available at https ://doi.
org/10.1186/s1290 5-021-01242 -3.
Additional file 1.Table S1. Characteristics of women aged 25-69 years 
diagnosed with cervical cancer in Norway by age, 1953-2013.
Additional file 2. Table S2. Hazard ratios (HRs) of cervical cancer mortal-
ity (with 95% CIs) overall and by period of diagnosis, with and without 




SL, GBS and TB conceived the study. BHG wrote the first draft of the manu-
script. TB performed the statistical analyses. All authors (BHG, SL, GBS, GS and 
TB) conceptualised the ideas, interpreted the findings and reviewed the drafts 
of the manuscript. All authors read and approved the final manuscript.
Funding
No specific funding was received for this study.
Availability of data and materials
The datasets analysed during the current study are not freely available due to 
national regulations.
Declarations
Ethics approval and consent to participate
The study and the researchers were approved by the Regional Committee 
for Medical and Health Research Ethics of Western Norway (REK ref. number 





The authors declare no conflicts of interest.
Author details
1 Department of Global Public Health and Primary Care, University of Bergen, 
5020 Bergen, Norway. 2 Cancer Registry of Norway, Oslo, Norway. 3 Norwegian 
Institute of Public Health, Bergen, Norway. 
Received: 27 October 2019   Accepted: 24 February 2021
References
 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global 
Cancer Statistics 2018: GLOBOCAN estimates of incidence and 
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 
2018;68(6):394–424.
 2. Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, et al. Esti-
mates of incidence and mortality of cervical cancer in 2018: a worldwide 
analysis. Lancet Glob Health. 2020;8:e191-203.
 3. Cancer Registry of Norway. Cervical cancer screening programme – 
Annual Report 2012 (in Norwegian). Oslo: Cancer Registry of Norway; 2014.
 4. Bjørge T, Gunbjørud AB, Langmark F, Skare GB, Thoresen SØ. Cervical 
mass screening in Norway–510,000 smears a year. Cancer Detect Prev. 
1994;18(6):463–70.
 5. Pedersen K, Fogelberg S, Thamsborg LH, Clements M, Nygård M, Kristian-
sen IS, et al. An overview of cervical cancer epidemiology and prevention 
in Scandinavia. Acta Obstet Gynecol Scand. 2018;97(7):795–807.
Page 8 of 8Gravdal et al. BMC Women’s Health          (2021) 21:110 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 6. Cancer Registry of Norway. Cervical cancer screening programme: 
organisation. https ://www.kreft regis teret .no/en/scree ning/cervi x/org. 
Accessed 21.02.2021.
 7. Cancer Registry of Norway. Cervical cancer screening programme – 
Annual Report 2015 (in Norwegian). Oslo: Cancer Registry of Norway; 2016.
 8. Engesæter B, van Diermen HB, Hansen M, Moltu P, Staby KM, Borch-
grevink-Persen S, et al. Quality assurance of human papillomavirus (HPV) 
testing in the implementation of HPV primary screening in Norway: an 
inter-laboratory reproducibility study. BMC. 2016;16:698.
 9. Lönnberg S, Hansen BT, Haldorsen T, Campbell S, Schee K, Nygård M. 
Cervical cancer prevented by screening: Long-term incidence trends by 
morphology in Norway. Int J Cancer. 2015;137(7):1758–64.
 10. Castanon A, Leung VM, Landy R, Lim AW, Sasieni P. Characteristics and 
screening history of women diagnosed with cervical cancer aged 20–29 
years. Br J Cancer. 2013;109(1):35–41.
 11. Foley G, Alston R, Geraci M, Brabin L, Kitchener H, Birch J. Increasing rates 
of cervical cancer in young women in England: an analysis of national 
data 1982–2006. Br J Cancer. 2011;105(1):177–84.
 12. Lancucki L, Fender M, Koukari A, Lynge E, Mai V, Mancini E, et al. A fall-off 
in cervical screening coverage of younger women in developed coun-
tries. J Med Screen. 2010;17(2):91–6.
 13. Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray 
F, et al. Data quality at the Cancer Registry of Norway: an overview 
of comparability, completeness, validity and timeliness. Eur J Cancer. 
2009;45(7):1218–31.
 14. Pedersen AG, Ellingsen CL. Data quality in the Causes of Death Registry. 
Tidsskr Nor Laegeforen. 2015;135(8):768–70.
 15. Bjørge T, Gunbjørud AB, Haugen OA, Skare GB, Tropé C, Thoresen SØ. 
Mass screening for cervical cancer in Norway: evaluation of the pilot 
project. Cancer Causes Control. 1995;6:477–84.
 16. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age 
standardization of rates: a new WHO standard. 2001.
 17. Dragomirescu I, Llorca J, Gomez-Acebo I, Dierssen-Sotos T. A join point 
regression analysis of trends in mortality due to osteoporosis in Spain. Sci 
Rep. 2019;9(1):4264.
 18. Aalen O. Nonparametric inference for a family of counting processes. 
Annals Statist. 1978;6:701–26.
 19. Nelson W. Theory and applications of hazard plotting for censored failure 
data. Technometrics. 1972;14:945–66.
 20. Landy R, Pesola F, Castanon A, Sasieni P. Impact of cervical screening on 
cervical cancer mortality: estimation using stage-specific results from a 
nested case-control study. Br J Cancer. 2016;115(9):1140–6.
 21. Lönnberg S, Anttila A, Luostarinen T, Nieminen P. Age-specific effec-
tiveness of the Finnish cervical cancer screening programme. Cancer 
Epidemiol Biomarkers Prev. 2012;21(8):1354–61.
 22. Lönnberg S, Nieminen P, Luostarinen T, Anttila A. Mortality audit 
of the Finnish cervical cancer screening program. Int J Cancer. 
2013;132(9):2134–40.
 23. Denstad SE, Aasen S, Ostrem AM, Bakkeheim V, Fossum GH, Moen MH. 
[Hysterectomy at St. Olavs Hospital 1989–2014]. Tidsskr Nor Laegeforen 
2017; 137(16).
 24. Domingo S, Pellicer A. Overview of Current Trends in Hysterectomy. 
Expert Rev of Obstet Gynecol. 2009;4(6):673–85.
 25. Moen MH. Different practice in hysterectomy. Tidsskr Nor Laegeforen. 
2004;124(6):767.
 26. Nygård JF, Skare GB, Thoresen SØ. The cervical cancer screening pro-
gramme in Norway, 1992–2000: changes in Pap smear coverage and 
incidence of cervical cancer. J Med Screen. 2002;9(2):86–91.
 27. Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of 
adenocarcinoma and adenosquamous carcinoma in younger women. 
CMAJ. 2001;164(8):1151–2.
 28. Beachler DC, Tota JE, Silver MI, Kreimer AR, Hildesheim A, Wentzensen 
N, et al. Trends in cervical cancer incidence in younger US women from 
2000 to 2013. Gynecol Oncol. 2017;144(2):391–5.
 29. Popadiuk C, Stankiewicz A, Dickinson J, Pogany L, Miller AB, Onysko 
J. Invasive cervical cancer incidence and mortality among canadian 
women aged 15 to 29 and the impact of screening. J Obstet Gynaecol 
Can. 2012;34(12):1167–76.
 30. Póká R, Juhász B, Lampé L. Cervical cancer in young women: a poorer 
prognosis? Int J Gynaecol Obstet. 1994;46(1):33–7.
 31. Sasieni P, Castanon A. Dramatic increase in cervical cancer registrations in 
young women in 2009 in England unlikely to be due to the new policy 
not to screen women aged 20–24. J Med Screen. 2012;19(3):127–32.
 32. Ponti A, Anttila A, Ronco G, Senore C, Basu P, Segnan N et al. Cancer 
Screening in the European Union (2017). https ://ec.europ a.eu/healt h/sites /
healt h/files /major _chron ic_disea ses/docs/2017_cance rscre ening _2ndre 
porti mplem entat ion_en.pdf.
 33. Landy R, Birke H, Castanon A, Sasieni P. Benefits and harms of cervical 
screening from age 20 years compared with screening from age 25 years. 
Br J Cancer. 2014;110(7):1841–6.
 34. Elfstrom KM, Arnheim-Dahlstrom L, von Karsa L, Dillner J. Cervical cancer 
screening in Europe: Quality assurance and organisation of programmes. 
Eur J Cancer. 2015;51(8):950–68.
 35. Steen R, Hagen B, Hagmar B, Iversen OE, Juvkam KH, Thoresen SØ, et al. 
What is the optimal age to start cervix screening? Tidsskr Nor Laegeforen. 
2008;128(3):339.
 36. Norwegian Institute of Public Health. National surveillance of HPV vac-
cination programme Internet https ://www.fhi.no/en/studi es/hpv-follo 
w-up/natio nal-surve illan ce-of-hpv-vacci natio n-progr amme/. Accessed 
21.02.2021.
 37. European Centre for Disease Prevention and Control. Introduction of 
HPV vaccines in European Union countries – an update. https ://ecdc.
europ a.eu/sites /porta l/files /media /en/publi catio ns/Publi catio ns/20120 
905_GUI_HPV_vacci ne_updat e.pdf (2012).
 38. Harper DM, DeMars LR. HPV vaccines - A review of the first decade. 
Gynecol Oncol. 2017;146(1):196–204.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
